Andrew I. Koven
Known title: DirectorCIK: 0001258673
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
KALA Bio Signs LOI to Acquire Telehealth Platform. KALA Bio shares surged 57% after hours following the announcement of a non-binding letter of intent to acquire a nationwide telehealth platform. The target company has generated approximately $48 million in sales since inception. Additionally, the company signed a separate agreement to resell genetic testing products through a U.S. DNA testing platform.
Transaction History
| MTVA | ▲ Buy | Grant | 17,186 | $0 | 6/8/2026 | View on chart |
| MTVA | ▲ Buy | Grant | 28,147 | $0 | 6/30/2025 | View on chart |
| KALA | ▲ Buy | Grant | 3,050 | $0 | 6/15/2025 | View on chart |
| KALA | ▲ Buy | Grant | 1,750 | $0 | 6/11/2024 | View on chart |
| MTVA | ▲ Buy | Grant | 5,051 | $0 | 6/7/2024 | View on chart |
| MTVA | ▲ Buy | Grant | 87,500 | $0 | 7/27/2023 | View on chart |
| MTVA | ▲ Buy | Grant | 12,500 | $0 | 7/27/2023 | View on chart |
| KALA | ▲ Buy | Grant | 7,515 | $0 | 6/22/2023 | View on chart |
| KALA | ▲ Buy | Grant | 1,400 | $0 | 6/22/2023 | View on chart |
| KALA | ▲ Buy | Grant | 2,197 | — | 5/31/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
MTVA appoints Dr. Sarah Browne as Chief Medical Officer
MetaVia announced the appointment of Dr. Sarah Browne, M.D., as its new chief medical officer. Dr. Browne brings extensive clinical development experience, which could support the company's ongoing drug development efforts. The move comes as the stock is trading near its $1.41 support level, a point that has been tested many times.
MTVA appoints Dr. Sarah Browne as Chief Medical Officer. MetaVia announced the appointment of Dr. Sarah Browne, M.D., as its new chief medical officer. Dr. Browne brings extensive clinical development experience, which could support the company's ongoing drug development efforts. The move comes as the stock is trading near its $1.41 support level, a point that has been tested many times.